GLP-1 Advisor | One Day MD

What should you eat while taking Ozempic, Wegovy, Mounjaro or Zepbound? The best diet is one that provides enough protein, fiber, vitamins, minerals and fluids while helping you manage hunger, preserve muscle and tolerate treatment. GLP-1 medications can reduce appetite and help you feel full sooner. They can also slow stomach emptying, which may make large meals, greasy foods and certain other foods uncomfortable. Because you may eat substantially less than before, the nutritional quality of each meal becomes especially important. This guide explains the best foods to eat on GLP-1 medications, which foods may worsen side effects, how to build balanced meals, and what a practical one-day eating plan looks like. Important: There is no single mandatory GLP-1 diet. Individual needs depend on your medication, treatment goals, medical history, food preferences and side effects. This guide is educational and does not replace individualized medical or dietetic advice. 1. ...

Last reviewed: October 17, 2026. This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are in US dollars and are subject to change. Manufacturer savings programs have eligibility rules and may expire. The cost of a GLP-1 medication in 2026 can range from under $200 per month for certain oral formulations or introductory self-pay offers to several hundred dollars per month for ongoing treatment. Insurance may lower the cost considerably, but coverage for obesity treatment is not guaranteed—even when a medication is medically appropriate. This guide compares Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (orforglipron), Ozempic, Mounjaro and other prescription options , with an emphasis on what patients may actually pay. Important: A manufacturer's advertised price is not necessarily your final pharmacy price. Confirm the exact product, prescribed dose, dispensing method, insurance benefit and savings-progra...

Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...